FDA Collates GMP Data Integrity Advice Into New Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
New Q&A-format draft guidance could help stave off the missteps flagged in recent warning letters, more of which focus on data integrity. One basic piece of advice: if data is generated to satisfy a CGMP requirement, then it is a CGMP record that must be retained.
You may also be interested in...
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.
US FDA Seeks More Power To Confront ‘Shadow’ Factory Challenges
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find manufacturer of contaminated eye drops that disappeared.